
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at trastuzumab deruxtecan for cancers that have a high number of the HER2 receptors (.
It is open to people with a cancer that has spread or cannot be removed by surgery. The types of cancers are listed in 'Who can enter'.
Trastuzumab deruxtecan is a combination of 2 drugs. Trastuzumab is a . Deruxtecan is similar to chemotherapy.
Trastuzumab attaches to receptors called HER2 found on cancer cells. Cancers that have a high number of this receptor are HER2 positive cancers. When trastuzumab attaches to these receptors it releases deruxtecan into the cancer cell.
Deruxtecan becomes active when it is in the cancer cell. It works in a similar way to some chemotherapy drugs by blocking an that cancer cells need to grow.
In some countries, doctors can use trastuzumab deruxtecan for HER2 positive breast cancer that has spread to other parts of the body.
Researchers think that trastuzumab deruxtecan might help people who have other cancers that are HER2 positive.
In this trial everyone has trastuzumab deruxtecan.
The main aims of the trial are to find out:
The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if you have one of the following cancers:
And all of the following apply. You:
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You have:
Medical conditions
You cannot join this trial if any of these apply. You:
Other
You cannot join this trial if any of these apply. You:
This is an international phase 2 trial. The trial team need 280 people worldwide to join with 6 people from the UK.
The team test a sample of tissue () to check you have large amounts of the HER2 protein on your cancer cells. Please note, you can’t take part in this trial if your cancer cells don’t have large amounts of the HER2 protein.
Everyone has trastuzumab deruxtecan. You have trastuzumab deruxtecan as a drip into a vein. You have it once a week every 3 weeks. This 3 week period is a .
You have the first treatment over 90 minutes. After this all other treatments are over 30 minutes if you didn’t have a reaction during the first treatment.
You continue having trastuzumab deruxtecan as long as it is working and the side effects aren’t too bad. You stop treatment if your cancer gets worse. Your doctor will talk to you about other treatment options.
Samples for research
You give extra blood samples during the trial. Whenever possible the team take these when you have your routine bloods.
The team ask you to give a number of tissue samples (biopsies) during the trial.
Researchers will use these blood and tissue samples to find out:
You need to agree to give most of the samples to take part in the trial. There are a few you don’t have to give. Your doctor or a member of the trial team will talk to you about the samples. They will tell you which ones you must agree to and which ones you don’t have to agree to.
You see the doctor to have tests before taking part. These tests include:
You see the doctor once a week for 3 weeks when you have your 1st treatment. You then see them once every 3 weeks on the day you have trastuzumab deruxtecan. This is to see how you are and to take bloods.
You have a CT scan or an MRI scan every 6 weeks.
When you stop treatment you either go to hospital or have a phone appointment. If you choose to go to the hospital you see the doctor within 7 days. If you choose not to go to the hospital the team will phone within 40 days. This to see how you are.
You then see the doctor every 3 months for 12 months. If your cancer has gets worse they will continue to see you every 3 months.
You continue to have a CT scan or an MRI scan every 6 weeks until your cancer gets worse.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
The most common side effects of trastuzumab deruxtecan are:
Trastuzumab deruxtecan might cause a serious lung problem. In some cases this could be life threatening. Symptoms are similar to other heart or lung diseases. Please contact your doctor straight away if you have any new lung symptoms or symptoms that are getting worse. These include:
|
Your doctor or a member of the trial team will talk to you about the possible side effects before you agree to take part.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Banerjee
AstraZeneca
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”